{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:32:42Z","timestamp":1776375162454,"version":"3.51.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Rhizen Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s10637-022-01315-6","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:45:46Z","timestamp":1680500746000},"page":"350-355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory s\u00e9zary syndrome"],"prefix":"10.1007","volume":"41","author":[{"given":"Christopher N.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swaminathan P.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajak J.","family":"Barde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasi Viswanath","family":"Routhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auris O.","family":"Huen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"1315_CR1","doi-asserted-by":"publisher","unstructured":"Hristov AC, Tejasvi T, A Wilcox R (2021) Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.\u00a0Am J Hematol 96(10):1313\u20131328. https:\/\/doi.org\/10.1002\/ajh.26299","DOI":"10.1002\/ajh.26299"},{"issue":"1","key":"1315_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.21037\/cco.2019.01.02","volume":"8","author":"O Alpdogan","year":"2019","unstructured":"Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P (2019) Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chin Clin Oncol 8(1):10. https:\/\/doi.org\/10.21037\/cco.2019.01.02","journal-title":"Chin Clin Oncol"},{"issue":"11","key":"1315_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","volume":"26","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Brown JR (2017) PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26(11):1267\u20131279. https:\/\/doi.org\/10.1080\/13543784.2017.1384815","journal-title":"Expert Opin Investig Drugs."},{"key":"1315_CR4","doi-asserted-by":"publisher","unstructured":"Huen A, Haverkos BM, Zain J et al (2020) Phase I\/Ib Study of Tenalisib (RP6530), a Dual PI3K \u03b4\/\u03b3 Inhibitor in Patients with Relapsed\/Refractory T-Cell Lymphoma.\u00a0Cancers (Basel) 12(8):2293. Published 2020 Aug 15. https:\/\/doi.org\/10.3390\/cancers12082293","DOI":"10.3390\/cancers12082293"},{"issue":"8","key":"1315_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Koch R, Porcu P et al (2018) Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131(8):888\u2013898. https:\/\/doi.org\/10.1182\/blood-2017-08-802470","journal-title":"Blood."},{"key":"1315_CR6","unstructured":"Safety and Efficacy of Tenalisib (RP6530) in Combination with Romidepsin in Patients with Relapsed\/Refractory T-cell Lymphoma.\u00a0Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03770000. Accessed 30 Apr 2022"},{"key":"1315_CR7","unstructured":"Compassionate Use Study of Tenalisib (RP6530).\u00a0Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03711604. Accessed 30 Apr 2022"},{"issue":"5","key":"1315_CR8","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.clml.2014.09.013","volume":"15","author":"M Polansky","year":"2015","unstructured":"Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M (2015) Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With S\u00e9zary Syndrome. Clin Lymphoma Myeloma Leuk 15(5):e83\u2013e93. https:\/\/doi.org\/10.1016\/j.clml.2014.09.013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"1315_CR9","doi-asserted-by":"publisher","unstructured":"Kim YH, Bagot M, Pinter-Brown L et al (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [published correction appears in Lancet Oncol. 2018 Nov;19(11):e581].\u00a0Lancet Oncol 19(9):1192\u20131204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"1315_CR10","doi-asserted-by":"publisher","unstructured":"Beygi S, Duran GE, Fernandez-Pol S, Rook AH, Kim YH, Khodadoust MS (2022) Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma [published online ahead of print, 2022 Apr 18].\u00a0Blood\u00a0blood.2021014468. https:\/\/doi.org\/10.1182\/blood.2021014468","DOI":"10.1182\/blood.2021014468"},{"issue":"1","key":"1315_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CF Hughes","year":"2015","unstructured":"Hughes CF, Khot A, McCormack C et al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and S\u00e9zary syndrome: a comparative study of systemic therapy. Blood 125(1):71\u201381. https:\/\/doi.org\/10.1182\/blood-2014-07-588236","journal-title":"Blood."},{"issue":"4","key":"1315_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","volume":"14","author":"R Talpur","year":"2014","unstructured":"Talpur R, Thompson A, Gangar P, Duvic M (2014) Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 14(4):297\u2013304. https:\/\/doi.org\/10.1016\/j.clml.2014.01.010","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"2","key":"1315_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2019.10.013","volume":"20","author":"C Carlo-Stella","year":"2020","unstructured":"Carlo-Stella C, Delarue R, Scarfo L et al (2020) A First-in-human Study of Tenalisib (RP6530), a Dual PI3K \u03b4\/\u03b3 Inhibitor, in Patients With Relapsed\/Refractory Hematologic Malignancies: Results From the European Study. Clin Lymphoma Myeloma Leuk 20(2):78\u201386. https:\/\/doi.org\/10.1016\/j.clml.2019.10.013","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"1315_CR14","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood-2018-99-112757","volume":"132","author":"SP Iyer","year":"2018","unstructured":"Iyer SP, Huen A, Ferreri AJM et al (2018) Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory lymphoid malignancies. Blood 132:2925. https:\/\/doi.org\/10.1182\/blood-2018-99-112757","journal-title":"Blood."},{"key":"1315_CR15","doi-asserted-by":"crossref","unstructured":"Iyer S, Huen A, Ai W et al (2021) Safety and efficacy of tenalisib given in combination with Romidepsin in patients with relapsed\/refractory T-Cell Lymphoma: Final results from a phase I\/II open label multi-center study. Blood (ASH Annual Meeting Abstracts)","DOI":"10.1182\/blood-2021-145851"},{"key":"1315_CR16","doi-asserted-by":"publisher","unstructured":"Kaneda MM, Messer KS, Ralainirina N et al (2016) PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539(7629):437\u2013442. https:\/\/doi.org\/10.1038\/nature19834","DOI":"10.1038\/nature19834"},{"key":"1315_CR17","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/blood.V122.21.4418.4418","volume":"22","author":"J Lewis","year":"2013","unstructured":"Lewis J, Girardi M, Vakkalanka S, Viswanadha S, Bertoni F (2013) RP6530, a dual PI3K\u03b4\/\u03b3 inhibitor, attenutates AKT phosphorylation and induces apoptosis in primary cutaneous T cell lymphoma (CTCL) cells. Blood 22:4418. https:\/\/doi.org\/10.1182\/blood.V122.21.4418.4418","journal-title":"Blood."}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01315-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01315-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T08:09:25Z","timestamp":1682582965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01315-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["1315"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01315-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors report there are no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}